The market is closing out the week on a high note, with the Dow Jones Industrial Average (DJINDICES:^DJI) up 26 points as of 2:35 p.m. EDT and still flirting with another record high. While the index has dropped a bit in afternoon trading, the majority of the index's member stocks remain in the green. Caterpillar (NYSE:CAT) is up 1.7% to become the big winner on the Dow so far today, even on lackluster sales news. Meanwhile, Shire Pharmaceuticals (NASDAQ:SHPG) shares have gained nearly 17%. Let's catch up on what you need to know.
Caterpillar sales under fire
Caterpillar's stock leaped more than 19% since 2014 kicked off, but the company is still working on how to turn around the ongoing sales slide of its heavy machinery. The industrial giant this week reported that its Asia-Pacific dealer sales declined by 30% in the three months ended in May, worsening a 25% slump in such sales from the three-month period through April. Overall dealer sales declined by 12% in the three months that ended in May, with even some of the company's best-performing regions feeling the hit from the mining sector's slump.
Mining has struggled to recover in the years since the recession ended. Caterpillar's resource industry group, which produces machinery for the mining sector, saw dealer sales slump by 69% in its Asia-Pacific business and by 47% in its Africa, Middle East, and European group. Only North America showed any sign of success over the latest three-month reporting period, as the resource industry saw a 7% increase in dealer sales. While the U.S.' ongoing housing rise and steady economic growth bode well for Caterpillar -- particularly as the company's largest geographic segment -- the company will need to ratchet up international revenue in the near future. Sales from outside of North America made up more than 60% of the company's overall revenue last year, and the Asia-Pacific region in particular saw a 28% overall revenue decline in 2013.
In the health-care sector, Shire's stock bloomed today after the company turned down the latest buyout bid in what has turned out to be a year dominated by merger and acquisition talk in the pharmaceutical industry. Big Pharma's AbbVie (NYSE:ABBV) offered more than $46 billion to acquire Shire, hoping to follow in the footsteps of Medtronic's recent big buyout of Covidien by snapping up a foreign competitor and incorporating abroad. AbbVie can maintain its pursuit of Shire until mid-July under U.K. rules before having to wait six months to try again, so this acquisition hunt may continue if AbbVie is gunning to lower its tax bill.
Shire, however, has made it clear that it's not biting. In a note saying that AbbVie's latest offer significantly undervalues the drugmaker, the company claimed that it can double its annual product revenue to $10 billion by 2020. Analysts have noted that AbbVie, which has made its name selling the world's top-selling drug, immunology therapy Humira, has little synergies with Shire in terms of drug specializations, so likely benefits would stem primarily from the tax savings of incorporating in a foreign nation, along with cost-cutting moves.
Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Covidien. The Motley Fool owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.